更新于：2024-06-20
Amorolfine Hydrochloride
盐酸阿莫罗芬
更新于：2024-06-20
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C21H36ClNO |
InChIKeyXZKWIPVTHGWDCF-KUZYQSSXSA-N |
CAS号78613-38-4 |
关联
16
项与 盐酸阿莫罗芬 相关的临床试验Q-switched Nd:YAG laser versus Amorolfine Hydrochloride Cream in treatment of Distal lateral subungual onychomycosis in older adults
Pilot Study on the Evaluation of the Efficacy, Tolerability and Safety of Topical and Oral Antifungals in the Treatment of Onychomycosis and Creation of a Library of Dermatological Clinical Isolates
AN OPEN RANDOMIZED COMPARATIVE STUDY TO TEST THE EFFICACY AND SAFETY OF DAILY ORAL ITRACONAZOLE AS A MONOTHERAPY AND IN COMBINATION WITH TOPICAL AMOROLFINE IN TINEA CORPORIS/CRURIS.
100 项与 盐酸阿莫罗芬 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿莫罗芬 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿莫罗芬 相关的专利（医药）
登录后查看更多信息
277
项与 盐酸阿莫罗芬 相关的文献（医药）2024-03-01Journal de mycologie medicale
Pythium insidiosum: In vitro oomicidal evaluation of telithromycin and interactions with azithromycin and amorolfine hydrochloride
Article
作者: Maciel, Aline Fontanella ; Ianiski, Lara Baccarin ; Botton, Sônia de Avila ; Sangioni, Luis Antônio ; Pal, Mahendra ; Pereira, Daniela Isabel Brayer ; Colla, Ana Carolina Nolasco ; Braga, Caroline Quintana ; Santurio, Janio Morais
This study evaluated the repositioning of the ketolide antibacterial telithromycin (TLT) against the oomycete Pythium insidiosum and verified the combination of TLT and the antimicrobials azithromycin (AZM) and amorolfine hydrochloride (AMR), which have known anti-P. insidiosum activity. Susceptibility tests of P. insidiosum isolates (n = 20) against the drugs were carried out according to CLSI protocol M38-A2, and their combinations were evaluated using the checkerboard microdilution method. The minimum inhibitory concentrations were 0.5-4 µg/mL for TLT, 2-32 µg/mL for AZM, and 16-64 µg/mL for AMR. For the TLT+AZM combination, 52.75 % of interactions were indifferent, 43.44 % were antagonistic, and 9.70 % were synergistic. As for interactions of the TLT+AMR combination, 60.43 % were indifferent, 39.12 % were antagonistic, and 10.44 % synergistic interactions. This study is the first to evaluate the repositioning of the antibacterial TLT against mammalian pathogenic oomycetes, and our results show that its isolated action is superior to its combinations with either AZM or AMR. Therefore, we recommend including TLT in future research to evaluate therapeutic approaches in different clinical forms of human and animal pythiosis.
2024-01-17Journal of clinical microbiology
Development of an agar-based screening method for terbinafine, itraconazole, and amorolfine susceptibility testing of
Trichophyton
spp.
Article
作者: Siopi, Maria ; Efstathiou, Ioanna ; Arendrup, Maiken C ; Meletiadis, Joseph
ABSTRACT:
Resistance in dermatophytes is an emerging global public health issue. We, therefore, developed an agar-based method for screening
Trichophyton
spp. susceptibility to terbinafine (TRB), itraconazole (ITC), and amorolfine (AMF) and validated it using molecularly characterized isolates. Α total of 40
Trichophyton
spp. isolates, 28 TRB wild type (WT) (13
T. rubrum
, 10
T. mentagrophytes
, 5
T. interdigitale
) and 12 TRB non-WT (7
T. rubrum
, 5
T. indotineae
) with different alterations in the squalene epoxidase (SQLE) gene, were used. The optimal test conditions (inoculum and drug concentrations, incubation time, and temperature) and stability over time were evaluated. The method was then applied for 86 WT
Trichophyton
spp. clinical isolates (68
T. rubrum
, 7
T. interdigitale
, 6
T. tonsurans
, 5
T. mentagrophytes
) and 4 non-WT
T. indotineae
. Optimal growth of drug-free controls was observed using an inoculum of 20 µL 0.5 McFarland after 5–7 days of incubation at 30°C. The optimal concentrations that prevented the growth of WT isolates were 0.016 mg/L of TRB, 1 mg/L of ITC, and 0.25 mg/L of AMF, whereas 0.125 mg/L of TRB was used for the detection of
Trichophyton
strong SQLE mutants (MIC ≥0.25 mg/L). The agar plates were stable up to 4 months. Inter-observer and inter-experimental agreement were 100%, and the method successfully detected TRB non-WT
Trichophyton
spp. strains showing 100% agreement with the reference EUCAST methodology. An agar-based method was developed for screening
Trichophyton
spp. in order to detect TRB non-WT weak and strong mutant isolates facilitating their detection in non-expert routine diagnostic laboratories.
2023-01-01Drugs in context
Tinea pedis: an updated review.
Review
作者: Barankin, Benjamin ; Lam, Joseph M ; Leong, Kin Fon ; Hon, Kam Lun ; Leung, Alexander Kc
Background:
Tinea pedis is one of the most common superficial fungal infections of the skin, with various clinical manifestations. This review aims to familiarize physicians with the clinical features, diagnosis and management of tinea pedis.
Methods:
A search was conducted in April 2023 in PubMed Clinical Queries using the key terms 'tinea pedis' OR 'athlete's foot'. The search strategy included all clinical trials, observational studies and reviews published in English within the past 10 years.
Results:
Tinea pedis is most often caused by Trichophyton rubrum and Trichophyton interdigitale. It is estimated that approximately 3% of the world population have tinea pedis. The prevalence is higher in adolescents and adults than in children. The peak age incidence is between 16 and 45 years of age. Tinea pedis is more common amongst males than females. Transmission amongst family members is the most common route, and transmission can also occur through indirect contact with contaminated belongings of the affected patient. Three main clinical forms of tinea pedis are recognized: interdigital, hyperkeratotic (moccasin-type) and vesiculobullous (inflammatory). The accuracy of clinical diagnosis of tinea pedis is low. A KOH wet-mount examination of skin scrapings of the active border of the lesion is recommended as a point-of-care testing. The diagnosis can be confirmed, if necessary, by fungal culture or culture-independent molecular tools of skin scrapings. Superficial or localized tinea pedis usually responds to topical antifungal therapy. Oral antifungal therapy should be reserved for severe disease, failed topical antifungal therapy, concomitant presence of onychomycosis or in immunocompromised patients.
Conclusion:
Topical antifungal therapy (once to twice daily for 1-6 weeks) is the mainstay of treatment for superficial or localized tinea pedis. Examples of topical antifungal agents include allylamines (e.g. terbinafine), azoles (e.g. ketoconazole), benzylamine, ciclopirox, tolnaftate and amorolfine. Oral antifungal agents used for the treatment of tinea pedis include terbinafine, itraconazole and fluconazole. Combined therapy with topical and oral antifungals may increase the cure rate. The prognosis is good with appropriate antifungal treatment. Untreated, the lesions may persist and progress.
100 项与 盐酸阿莫罗芬 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 真菌病 | 中国 | 2000-04-10 | |
| 传染性皮肤病 | 中国 | 2000-04-10 | |
| 皮肤念珠菌病 | 日本 | 1993-10-01 | |
| 银屑病 | 日本 | 1993-10-01 | |
| 足癣 | 日本 | 1993-10-01 | |
| 白癜风 | 日本 | 1993-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 50 | (Loceryl NL+Cosmetic Varnish) | 願鬱觸糧鏇構獵遞膚選(選鏇築廠選鬱齋獵製製) = 遞齋願鏇艱蓋糧壓餘廠 構構醖憲鹽製積製構鑰 (齋衊鹽餘齋顧齋範構鹽, 簾壓選鬱壓夢顧簾淵遞 ~ 蓋齋構夢襯範網襯艱衊) 更多 | - | 2018-10-09 | ||
(Loceryl NL 12 Weeks) | 願鬱觸糧鏇構獵遞膚選(選鏇築廠選鬱齋獵製製) = 遞廠觸築鹹蓋製窪襯糧 構構醖憲鹽製積製構鑰 (齋衊鹽餘齋顧齋範構鹽, 衊膚餘蓋淵製糧鏇艱鹽 ~ 蓋鑰觸構鹽襯選窪積蓋) 更多 | ||||||
临床4期 | 20 | (Loceryl NL) | 鏇齋鬱鏇鹹積願鏇醖遞(鬱廠衊壓蓋觸鹽選夢積) = 蓋壓鏇鏇齋繭繭壓製鏇 網夢蓋觸範獵淵淵夢夢 (網淵艱願遞製蓋鑰鬱鏇, 鑰壓鹽鬱憲鏇積鹹鬱襯 ~ 衊壓糧膚蓋糧鹹鏇鬱壓) 更多 | - | 2018-10-03 | ||
(Ciclopirox NL) | 鏇齋鬱鏇鹹積願鏇醖遞(鬱廠衊壓蓋觸鹽選夢積) = 顧夢鬱鏇積餘夢夢構鹽 網夢蓋觸範獵淵淵夢夢 (網淵艱願遞製蓋鑰鬱鏇, 襯艱選鹽顧餘獵選夢鏇 ~ 淵夢範齋鏇淵醖膚鹽鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用